Centessa Pharmaceuticals plc
CNTA
株式のランク
#2964
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical... Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.
株価
$40.50
最終同期: 2026-06-29
時価総額
$6.22B
変化（1日）
0.00%
変化（1年）
77.71%
国
GB
取引 Centessa Pharmaceuticals plc (CNTA)
カテゴリー
Healthcare
Centessa Pharmaceuticals plc（CNTA）のP/E比率
October 2026 時点のP/E比率 TTM -22.75
Centessa Pharmaceuticals plc の最新の財務報告および株価によると、現在の P/E (TTM) は -22.75 です。2023 年末時点での P/E は -5.07 でした。
Centessa Pharmaceuticals plc の P/E 比率の履歴（2019 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | -22.75 | 179.86% |
| 2024 | -8.13 | 60.50% |
| 2023 | -5.07 | 278.38% |
| 2022 | -1.34 | -98.59% |
| 2021 | -95.03 | -34.28% |
| 2020 | -144.60 | -67.01% |
| 2019 | -438.27 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 28.78 | -226.50% |
US
|
|
| -28.36 | 24.64% |
US
|
|
| -24.57 | 7.97% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -233.30% |
NL
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。